Cargando…

Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes

Detalles Bibliográficos
Autores principales:	Majewski, Colleen, Bakris, George L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2015
Materias:	Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876696/ https://www.ncbi.nlm.nih.gov/pubmed/25715414 http://dx.doi.org/10.2337/dc14-1596

Ejemplares similares

SGLT2 Inhibitors: The Latest “New Kids on the Block”!
por: Cefalu, William T., et al.
Publicado: (2015)

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2015)

Characteristics of urinary sodium excretion in patients with chronic kidney disease in Jiangsu, China
por: Sun, Lianqin, et al.
Publicado: (2021)

Assessment and validation of three spot urine assay methods for the estimation of 24‐hour urinary sodium excretion in Chinese Tibetan adults living in the mountains
por: Zhang, Xin, et al.
Publicado: (2021)

Relationship between 24‐hour urinary sodium excretion and blood pressure in the adult population in Shandong, China
por: Han, Weizhong, et al.
Publicado: (2019)

Estimating 24-h urinary sodium/potassium ratio from casual (‘spot’) urinary sodium/potassium ratio: the INTERSALT Study
por: Iwahori, Toshiyuki, et al.
Publicado: (2017)

Survey on sodium and potassium intake in patients with hypertension in China
por: Sun, Ningling, et al.
Publicado: (2021)

Global cardiovascular diseases burden attributable to high sodium intake from 1990 to 2019
por: Wang, Keke, et al.
Publicado: (2023)

Dietary sodium/potassium intake and cognitive impairment in older patients with hypertension: Data from NHANES 2011–2014
por: Kou, Chengkun, et al.
Publicado: (2023)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study
por: Okada, Kenta, et al.
Publicado: (2020)

Effects of Sodium Glucose Cotransporter 2 Inhibitor on Renal Renin-Angiotensin-Aldsoterone System
por: Takeda, Yoshiyu, et al.
Publicado: (2021)

ODP175 COVID-19 Induced Euglycemic Diabetic Ketoacidosis in a Patient taking Sodium-Glucose Cotransporter-2 Inhibitors
por: Alqaisi, Sura, et al.
Publicado: (2022)

SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor
por: Attia, Jonven, et al.
Publicado: (2019)

SAT110 Euglycemic Diabetes Ketoacidosis Associated With Sodium-glucose Cotransporter Inhibitors: A Case Series To Raise Awareness
por: Katwal, Dilasha, et al.
Publicado: (2023)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
por: Kao, Ting-Wei, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
por: Kalra, Sanjay, et al.
Publicado: (2016)

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
por: Patel, Dhiren K., et al.
Publicado: (2019)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
por: Xiang, Boyang, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
por: Kubota, Yoshiaki, et al.
Publicado: (2022)

Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
por: Chen, KangYu, et al.
Publicado: (2023)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
por: Sheu, Wayne H‐H
Publicado: (2020)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

THU338 Risks Of Stroke, Its Subtypes And Atrial Fibrillation Associated With Glucagon-like Peptide 1 Receptor Agonists Versus Sodium-glucose Cotransporter 2 Inhibitors: A Real-world Population-based Study In Hong Kong
por: Lui, David, et al.
Publicado: (2023)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
por: Gilbert, Richard E., et al.
Publicado: (2019)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Rossing, Peter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m7uj61ijui303qldoll17nedvc